What Is Halotestin? Half-Life, Dosing & How to Track It

What Halotestin is and how it works

Halotestin is the trade name for fluoxymesterone, a testosterone derivative modified with both a 9-alpha-fluoro group and an 11-beta-hydroxyl group in addition to the 17-alpha-alkylation shared by most orals in this batch. It carried FDA approval for treating certain hormone-responsive breast cancers and male hypogonadism, though those indications are now largely handled by newer drug classes and its clinical use has fallen off sharply.

Despite being testosterone-derived rather than DHT-derived, the fluorination and hydroxylation block meaningful aromatization, so — like the DHT-based orals in this batch — it does not raise estradiol. Its on-paper anabolic-to-androgenic assay rating is actually high — by that lab measure it isn’t a low-anabolic compound — but its real-world reputation runs the other way: the strength and combat-sport communities that have historically favored it describe effects that feel heavily androgenic (strength, aggression, CNS stimulation) with comparatively little visible muscle mass, a mismatch between assay data and lived experience rather than a straightforward pharmacological fact.

That real-world androgenic-leaning reputation does not make it "safer" — Halotestin combines 17-alpha-alkylation with high overall potency, and the liver-injury literature reflects that combination clearly.

Oral dosing & half-life

A half-life of roughly 6–9 hours supports a once- or twice-daily tablet schedule. Historical medical dosing was in the low single digits to low tens of milligrams — this is not a high-mg compound, which is exactly why its liver-injury risk at those amounts is worth taking seriously rather than assuming a small number means small risk.

Tablets are manufactured in small strengths reflecting that potency.

Tablet strengths shown reflect what is commonly manufactured, not a recommended total — given this compound’s hepatotoxicity profile, the monitoring section below matters more than the dosing table.

What makes orals different from injectables

Halotestin follows the same first-pass liver route as any swallowed steroid, and the 17-alpha-alkyl group is what lets it survive that pass — the standard trade-off across this drug class. What makes Halotestin distinct is that this liver-first metabolism is paired with a compound that is both highly potent and structurally modified in ways (fluorination, hydroxylation) associated with a notably sharper liver-injury signal in the case literature than most other orals.

An injectable ester never takes this route at all, which is the core reason "oral vs injectable" is treated as a meaningfully different risk category rather than a matter of preference.

What to monitor & the real risks

Liver monitoring is the priority here: Halotestin is widely regarded as one of the more hepatotoxic orals available, with liver enzyme elevation and, in case reports, cholestasis documented even at modest doses and durations. A baseline ALT/AST panel before starting and regular follow-up during any use is essential, not optional.

A lipid panel deserves close attention too — HDL suppression with Halotestin is often reported as more pronounced than with milder orals — along with routine blood pressure checks. Because it does not aromatize, water retention is not the concern here; the liver and lipid effects are. Avoiding other hepatotoxic exposures (including alcohol) during any use is a reasonable harm-reduction step given how sharply this compound is associated with liver strain.

Frequently asked questions